Considerations for Ensuring Safety and Efficacy of Vaccines and Therapeutic Proteins Manufactured by Using Platform Approaches Summary of a Workshop (2010) / Chapter Skim
Currently Skimming:
Appendix C Biographies
Appendix C Biographies
Pages 19-26
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 19... ...
Dr. HunterCevera served on Governor Ehrlich's Technology Commission and the Governor's Executive Council for Transition, and chairs the MD Technology Development Corporation Board of Directors.
|
From page 20... ...
Dr. Drew has expertise in chemical, biologic, and engineering technology for bulk manufacture of pharmaceuticals; capital project engineering; process safety testing and engineering; process control systems; information systems; fermentation and isolation process engineering for injectable antibiotics; anthelmintics; growth permitants; human and animal vaccines, including recombinant biologics; automated fermentation analyses; process control strategies for chemical and biologic processes; nanotechnology, biotechnology, and chemistry; intelligence and threat analysis; sensor systems; and weapons.
|
From page 21... ...
Speakers and Invited Discussants: Brian Kelley, PhD, is the senior director of bioprocess development at Genentech, which is responsible for development, validation, and technology transfer of fermentation, cellculture, chromatography, and filtration steps for the production of recombinant therapeutic proteins derived from mammalian and bacterial hosts. He joined Genentech in 2007 after working for 15 years at Genetics Institute.
|
From page 22... ...
Dr. Benet is a recipient of the AAPS Distinguished Pharmaceutical Scientist Award, the American Pharmaceutical Association Higuchi Research Prize, the American Society for Clinical Pharmacology Rawls-Palmer Award for Progress in Medicine, the International Pharmaceutical Federation (FIP)
|
From page 23... ...
He has served in various capacities in the American Chemical Society Division of Biochemical Technology: he has been 2003 division program cochair, division secretary in 2004–2006, and Web Seminar Program coordinator since 2005, and he has been named the 2010 cochair for recovery of biologic products. He received the James M
|
From page 24... ...
Before going to NIH, Dr. Gomez spent over 9 years at Abbott Laboratories, Sanofi Pasteur, and Baxter Healthcare in positions of increasing responsibility, leading process and product development organizations and project teams for multiple biologic products.
|
From page 25... ...
After a successful application to the Transformational Medical Technologies Initiative of the Defense Threat Reduction Agency (DTRA) , Evolva is now applying its novel drugdiscovery engine to generate novel immunomodulators, antivirals, and antibacterials for DTRA.
|
From page 26... ...
Dr. Marks has served on Department of Health and Human Services and National Institute of Allergy and Infectious Diseases expert advisory panels on the botulinum neurotoxins.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.